Description

Mavacamten 2.5mg Capsules

Mavacamten 2.5mg Capsules represent a revolutionary, first-in-class therapeutic approach for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Pharmacologically, this medication acts as a selective cardiac myosin inhibitor. In patients with HCM, the heart muscle (specifically the sarcomere) contracts too forcefully and has difficulty relaxing due to an excessive number of myosin heads forming cross-bridges with actin filaments.

Mavacamten 2.5mg Capsules work by binding to cardiac myosin and reducing the number of these active actin-myosin cross-bridges. It shifts the myosin population towards a “super-relaxed” (SRX) state, which prevents them from engaging in the contraction cycle. This targeted mechanism directly addresses the underlying pathophysiology of the disease: it dampens the hyper-contractility of the left ventricle and improves diastolic compliance (relaxation). Consequently, this reduces the dynamic obstruction of blood flow out of the heart and lowers the high pressures within the left ventricle, leading to significant symptomatic relief.

Indications / Uses of Mavacamten 2.5mg Capsules

Mavacamten 2.5mg Capsules are indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM). The primary goals of therapy include:

• Functional Capacity Improvement: Indicated to improve exercise capacity and NYHA functional class, allowing patients to engage in daily activities with less fatigue and shortness of breath.
• Reduction of LVOT Gradient: Used to significantly lower the Left Ventricular Outflow Tract (LVOT) gradient, which is the pressure difference caused by the obstruction of blood leaving the heart.
• Symptom Management: Prescribed to alleviate the burden of oHCM symptoms, such as chest pain (angina), palpitations, and exertional dyspnea.
• Alternative to Surgery: In many cases, it serves as an alternative to invasive septal reduction therapies (such as septal myectomy or alcohol septal ablation) for patients who are not candidates for or wish to avoid surgery.

Key Features

• Pathophysiology-Targeted: Unlike beta-blockers or calcium channel blockers that manage symptoms non-specifically, Mavacamten targets the molecular source of the disease (excessive cross-bridging).
• Oral Administration: The medication is formulated as a capsule taken once daily, offering a convenient, non-invasive treatment option.
• Precision Dosing: The 2.5mg strength is a critical starting dose or titration step, allowing healthcare providers to carefully adjust exposure based on the patient’s metabolic response and echocardiogram results.
• Diastolic Improvement: Beyond reducing obstruction, it enhances the heart’s ability to fill with blood during the relaxation phase, addressing a key component of heart failure in HCM.

Storage for Mavacamten 2.5mg Capsules

To ensure the stability and safety of Mavacamten 2.5mg Capsules, proper storage is strictly required. Store the medication at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Brief excursions are permitted between 15°C and 30°C (59°F to 86°F). Keep the capsules in their original container to protect them from moisture and light. Do not store the medication in humid environments like bathrooms. Ensure the bottle is tightly closed after every use and kept securely out of the reach and sight of children and pets.

Important Note on Mavacamten 2.5mg Capsules

Treatment with Mavacamten 2.5mg Capsules carries a Boxed Warning for the risk of heart failure. By reducing the heart’s contractility, the drug can cause the Left Ventricular Ejection Fraction (LVEF) to drop below normal levels (systolic dysfunction). Therefore, LVEF must be assessed by echocardiogram prior to initiation and regularly during treatment. If LVEF drops below 50%, the medication must be interrupted.

Due to this risk, Mavacamten is available only through a restricted distribution program called the Camzyos REMS Program. Both prescribers and patients must be enrolled.

Significant drug interactions exist, particularly with CYP2C19 and CYP3A4 inhibitors and inducers. Concomitant use with moderate to strong CYP2C19 inhibitors (e.g., omeprazole) or strong CYP3A4 inhibitors can dangerously increase drug levels and the risk of heart failure. Conversely, inducers can reduce efficacy.

Mavacamten can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for 4 months after the final dose. Mavacamten may reduce the effectiveness of hormonal contraceptives, so non-hormonal methods are recommended. Always inform your cardiologist of all other medications you are taking.